Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Urexent
- Development stage
- Preclinical
- Lead developer
- FBM Pharma
- Administration
- Oral
01
Overview
**Urexent** is a patient-specific, urine-derived oral drop preparation developed for immune modulation. It is manufactured from a patient's own urine, from which endogenous biochemical and immunological constituents are processed into an individualized product. Public product communications have described its intended use in infants, children, and adolescents with allergic diseases and increased susceptibility to infections, claiming restoration or support of immune function. Its precise molecular composition, pharmacologically validated target, and evidence-based mechanism of action have not been publicly defined.
- Brand names
- Urexent
Beyond the preview
Go deeper on Urexent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Urexent.